Procept BioRobotics Q2 revenue beats estimates on HYDROS demand
PRCT•Q2 revenue beats estimates
Procept BioRobotics said second-quarter revenue rose 19% year over year, beating analyst expectations as demand for its HYDROS system drove record placements and stronger replacement activity.
The surgical robotics company also said higher U.S. procedure volume supported handpiece and consumable sales.
Full-year 2026 outlook reiterated
Procept reiterated its 2026 revenue guidance of $390 million to $410 million.
The company expects 2026 U.S. procedure volume of 54,000 to 56,000, up 25% to 29% year over year, and sees adjusted EBITDA loss of $35 million to $30 million.
Key reported figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $94.50 million | $92.89 million (14 analysts) |
| Q2 Net Loss | $26.86 million |
The current average analyst rating on the shares is "buy," with 7 "strong buy" or "buy" ratings, 7 "hold" ratings and 1 "sell" or "strong sell" rating. Wall Street's median 12-month price target for Procept Biorobotics Corp is $29.50, about 60.5% above its Aug. 3 closing price of $18.38.
Loss widens on higher operating expenses
The company posted a wider net loss and adjusted EBITDA loss in the quarter, which it attributed to higher operating expenses.
Higher average selling prices and a $2.9 million tariff refund also contributed to gross margin improvement.
